A comparison of retrospective and concurrent drug utilization review of omeprazole

Journal of Pharmacy Technology

Volumn 14, Issue 5, 1998, Pages 202-208

  Chabot, Isabelle ^a   Morin, Johanne ^b   Bourbeau, Kateri ^a   Moisan, Jocelyne ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ARTICLE; COMPARATIVE STUDY; DRUG USE; DRUG UTILIZATION; PRESCRIPTION; QUALITY CONTROL; RETROSPECTIVE STUDY; UTILIZATION REVIEW;

EID: 0031714950     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259801400507     Document Type: Article

References (53)

1. Einarson TR, Segal HJ, Mann JL. Drug utilization in Canada. J Soc Adm Pharm 1989;6:69-82.
2. Soumerai SB, Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Q 1984;62:447-75.
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-56.
4. Blackburn JL. Impact of drug usage review on drug utilization. Pharmacoeconomics 1993;3:14-21.
5. Réseau de Revue d'Utilisation des Médicaments. L'ABC de la revue d'utilisation des médicaments. Montréal: Réseau de Revue d'Utilisation des Médicaments, 1992.
6. Bourbeau K, Gervais M. Le programme "revue d'utilisation des médicaments." Can J Hosp Pharm 1986;39:53-6.
7. Strong DK, Domaratzki JL. Pharmacist intervention in prescribing of cefuroxime for pediatrie patients. Am J Hosp Pharm 1990;47: 1350-3.
8. Réseau de Revue d'Utilisation des Médicaments. Revue d'utilisation de l'oméprazole, rapport individuel-Hôpital Laval. Montréal: Réseau de Revue d'Utilisation des Médicaments, 1994.
9. Oméprazole. La Lettre Médicale 1990;13:107-9.
10. Malon PN. Omeprazole. N Engl J Med 1991;324:965-75.
11. McTawish D, Buckley MMT, Heel RC. Omeprazole: an update of its pharmacology and therapeutic use in acid related disorders. Drugs 1991;42:138-70.
12. McQuaid KR, Isengerg JI. Medical therapy of peptic ulcer disease. Surg Clin North Am 1992;12:285-316.
13. Rubin W. Medical treatment of peptic ulcer disease. Med Clin North Am 1991;75:981-98.
14. Bardhan KD. Omeprazole in the management of refractory duodenal ulcer. Scand J Gastroenterol 1989;24(suppl 166):63-73.
15. 2-receptor antagonists: a controlled clinical trial. Gut 1991;32:435-8.
16. 2-resistant gastroduodenal ulcers (abstract). Gastroenterology 1988;94(part 2):A348.
17. Bianchi Porro G, Parente F. "Difficult" duodenal ulcer patients: clinical and therapeutic problems. Dig Dis 1991;9:219-28.
18. Meuwissen SG, Klinkenberg-Knol EC. Management of gastro-oesophageal reflux disease: are there alternatives to omeprazole? Digestion 1989;44(suppl 1):54-62.
19. Tytgat GN, Nio CY, Schotborgh RH. Reflux oesophagitis. Scand J Gastroenterol 1990;25(suppl 175):1-12.
20. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux oesophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988;23:625-32.
21. Bate CM, Keeling PW, O'Morain C, Wilkinson SP, Foster DN, Mountford RA, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic and histological evaluations. Gut 1990;31:968-72.
22. Adams MH, Ostrosky JD, Kirkwood CF. Therapeutic evaluation of omeprazole. Clin Pharm 1988;7:725-45.
23. Howard JM. Omeprazole in the treatment of gastroesophageal reflux disease. Can J Gastroenterol 1989;3(suppl A):62A-6A.
24. Santag SJ. The medical management of reflux oesophagitis: role of antacid and acid inhibition. Gastroenterol Clin North Am 1990; 19:683-712.
25. 2-receptor antagonists. Digestion 1989;44 (suppl 1):47-53.
26. Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RF, Jones RB, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 1990;31:745-9.
27. Klinkenberg-Knol EC, Jansen JBJM, de Bruyve JW. Long-term efficacy and safety of omeprazole in healing and prevention of patients with reflux oesophagitis (abstract). Gastroenterology 1988;9 (part 2):A230.
28. 2-receptor antagonists (abstract). Scand J Gastroenterol 1989;24(suppl 166):176.
29. 2-receptor antagonists. Scand J Gastroenterol 1989;24(suppl 166):88-93.
30. Lundell L, Backman L, Ekström P, Enander LK, Falkmer S, Fausa O, et al. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991;26:248-56.
31. 2-receptor antagonists. Aliment Pharmacol Ther 1990;4:593-9.
32. Lampkin TA, Ouellet D, Hak LJ, Dukes GE. Omeprazole: a novel anti-secretory agent for the treatment of acid-peptic disorders. DICP Ann Pharmacother 1990;24:393-402.
33. Lloyd-Davies KA, Rutgersson K, Sölvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4 year international study. Aliment Pharmacol Ther 1988;2:13-22.
34. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:394-404.
35. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989;97:827-36.
36. Hirschowitz BI, Deren J, Raufman JP, LaMont B, Berman R, Humphries T. A multicenter US study of omeprazole treatment of Zollinger-Ellison syndrome (ZES) (abstract). Gastroenterology 1988; 94(5 part 2):A188.
37. National Institutes of Health. Helicobacter pylori in peptic ulcer disease: NIH consensus conference. JAMA 1994;272:65-9.
38. Peura DA, Graham DY. Helicobacter pylori: consensus reached. Peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994;89:1137-9.
39. Veldhuyzen van Zanten SJ, Sherman PM. Indications for treatment of Heliocbacter pylori infection: a systematic overview. Can Med Assoc J 1994;150:189-98.
40. Hopkins RJ, Morris JG. Heliocbacter pylori: the missing link in perspective. Am J Med 1994;97:265-77.
41. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
42. Bianchi Porro G, Parente F. Long-term treatment of duodenal ulcer: a review of management options. Drugs 1991;4:38-51.
43. Earnest DL. Maintenance therapy in peptic ulcer disease. Med Clin North Am 1991;75:1013-38.
44. Jansen JB, Lamers CB. Omeprazole in the short-term treatment of reflux oesophagitis. Digestion 1989;44(suppl 1):40-6.
45. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
46. Sölvell L. The clinical safety of omeprazole. Scand J Gastroenterol 1989;24(suppl 166):106-10.
47. Tatro DS, Olin BR, Hebel SK. Drug interaction facts. St. Louis: Facts and Comparisons, Inc., 1992.
48. Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarine in healthy men. Ther Drug Monit 1989;11:176-84.
49. Anderson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
50. Berbatis CG, Maher MJ, Plumridge RJ, Stoelwinder JU, Zubrick SR. Impact of a drug bulletin on prescribing oral analgesics in a teaching hospital. Am J Hosp Pharm 1982;39:98-100.
51. May FE, Stewart RB, Cluff LE. Drug use in the hospital: evaluation of determinants. Clin Pharm Ther 1974;16(5 part 1):834-45.
52. Schroeder NH, Caffey EM Jr, Lorei TW. Anti-psychotic drugs: can education change prescribing practices? J Clin Psychiatry 1979; 40:186-9.
53. Gin AS, Laureen A, Honcharik L. Impact of a target drug monitoring program on the usage of clindamycin. Can J Hosp Pharm 1994;47:53-8.